S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
Log in

Takeda Pharmaceutical Stock Price, Forecast & Analysis (NYSE:TAK)

$20.03
+0.41 (+2.09 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$19.90
Now: $20.03
$20.05
50-Day Range
$16.90
MA: $17.82
$20.07
52-Week Range
$15.50
Now: $20.03
$21.61
Volume33,231 shs
Average Volume2.42 million shs
Market Capitalization$62.44 billion
P/E Ratio39.27
Dividend Yield3.09%
Beta0.7
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone813-3278-2306

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.88 billion
Cash Flow$2.19 per share
Book Value$29.75 per share

Profitability

Net Income$982.13 million

Miscellaneous

Employees49,578
Outstanding Shares3,117,140,000
Market Cap$62.44 billion
Next Earnings Date2/7/2020 (Estimated)
OptionableOptionable

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.


Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co Ltd (NYSE:TAK) released its quarterly earnings results on Thursday, October, 31st. The company reported $0.59 earnings per share (EPS) for the quarter. The firm earned $7.56 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.66% and a return on equity of 12.52%. View Takeda Pharmaceutical's Earnings History.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Takeda Pharmaceutical.

What price target have analysts set for TAK?

4 analysts have issued 12-month price objectives for Takeda Pharmaceutical's stock. Their forecasts range from $19.50 to $19.50. On average, they anticipate Takeda Pharmaceutical's stock price to reach $19.50 in the next twelve months. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for Takeda Pharmaceutical.

What is the consensus analysts' recommendation for Takeda Pharmaceutical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Takeda Pharmaceutical.

Has Takeda Pharmaceutical been receiving favorable news coverage?

Headlines about TAK stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Takeda Pharmaceutical earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Takeda Pharmaceutical.

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), CVS Health (CVS), Alibaba Group (BABA), Home Depot (HD), Johnson & Johnson (JNJ), Procter & Gamble (PG), Verizon Communications (VZ), General Electric (GE), The Coca-Cola (KO) and QUALCOMM (QCOM).

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the folowing people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)
  • Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)
  • Dr. Seigo Izumo M.D., Chair of Management Board
  • Mr. Costa Saroukos, Chief Financial Officer (Age 48)
  • Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62)

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional investors include Adelphi Capital LLP (0.29%), Mondrian Investment Partners LTD (0.12%), First Trust Advisors LP (0.07%), CIBC Asset Management Inc (0.04%), Sector Gamma AS (0.03%) and Oppenheimer Asset Management Inc. (0.01%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Exane Asset Management, CIBC Asset Management Inc, Regentatlantic Capital LLC, DNB Asset Management AS, Dividend Assets Capital LLC, D.A. Davidson & CO., World Asset Management Inc and Comerica Bank.

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was purchased by a variety of institutional investors in the last quarter, including Adelphi Capital LLP, First Trust Advisors LP, Mondrian Investment Partners LTD, Envestnet Asset Management Inc., Sector Gamma AS, Heritage Investors Management Corp, Yorktown Management & Research Co Inc and AdvisorNet Financial Inc.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $20.03.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $62.44 billion and generates $18.88 billion in revenue each year. The company earns $982.13 million in net income (profit) each year or $0.51 on an earnings per share basis. Takeda Pharmaceutical employs 49,578 workers across the globe.View Additional Information About Takeda Pharmaceutical.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is http://www.takeda.com/.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo M0, 103-8668. The company can be reached via phone at 813-3278-2306.


MarketBeat Community Rating for Takeda Pharmaceutical (NYSE TAK)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TAK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TAK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Producer Price Index (PPI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel